Brief: Celsion Corp Engages Bioqual For Non-Human Primate Challenge Study With Its SARS-COV-2 Vaccine

Imunon

31/01/2022 13:38

Jan 31 (Reuters) - Celsion Corp  CLSN.O :
    * CELSION CORPORATION ADVANCES PROOF OF CONCEPT TO NON-HUMAN
PRIMATE CHALLENGE STUDY AGAINST SARS-COV-2 WITH IN-PROCESS
VACCINE CANDIDATE
    * CELSION CORP - HAS ENGAGED BIOQUAL, INC TO CONDUCT A
NON-HUMAN
PRIMATE CHALLENGE STUDY WITH CELSION'S DNA-BASED APPROACH FOR A
SARS-COV-2 VACCINE
    * CELSION CORP - NHP PILOT STUDY  WILL EVALUATE COMPANY'S
LEAD
VACCINE FORMULATIONS FOR SAFETY, IMMUNOGENICITY AND PROTECTION
AGAINST SARS-COV-2
    * CELSION CORP - EXPECT NHP STUDIES TO BEGIN DURING Q2 OF
2022

Source text for Eikon:  ID:nGNX84vkBC 
Further company coverage:  CLSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))